Inhibition of Acetylcholinesterase and Butyrylcholinesterase by a Plant Secondary Metabolite Boldine

Adam Kostelnik¹,² and Miroslav Pohanka²

¹Faculty of Chemical Technology, University of Pardubice, 532 10 Pardubice, Czech Republic
²Faculty of Military Health Sciences, University of Defence, 500 10 Hradec Kralove, Czech Republic

Correspondence should be addressed to Miroslav Pohanka; miroslav.pohanka@gmail.com

Received 8 December 2017; Revised 13 February 2018; Accepted 27 February 2018; Published 5 April 2018

Academic Editor: Davor Zeljezic

Copyright © 2018 Adam Kostelnik and Miroslav Pohanka. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction
Cholinesterases are enzymes splitting esters of choline. We distinguish two enzymes belonging to the group of cholinesterases, AChE which is present in nervous system and terminates neurotransmission and BChE occurring in serum but the particular function of the enzyme remains undiscovered [1, 2]. They are sensitive to broad spectrum of molecules; many of them have artificial origin (e.g., organophosphate and carbamate pesticides or nerve agents) [3]. Research on natural inhibitors which brought substances like physostigmine or galantamine was started long time ago, lately their synthetic versions were also introduced [4, 5].

Boldine, in chemical terminology (S)-2,9-dihydroxy-1,10-dimethoxy-aporphine (Figure 1), is a natural alkaloid with reported antioxidant activity. It was isolated from dozens of plant species from Monimiaceae and Magnoliaceae [6, 7] and recently it was reported to inhibit AChE with IC₅₀ equal to 8.5 μmol/l [8]; thus it could be potential cholinesterase inhibitor. In this work, we reinvestigated its effect on AChE and also BChE and calculated IC₅₀ for both of them. We tried to propose mechanism of interaction of boldine with both cholinesterases as no evidence in literature about this interaction was found. Discussion of potential toxic effect in real conditions is also given. We hypothesize that boldine would serve as a structure for pharmacology research and, furthermore, boldine would act as a multitarget toxin. Unfortunately, data about boldine impact on targeted receptor site are scattered. We decided to investigate interaction between boldine and AChE in higher details than currently available.

2. Material and Methods
2.1. Chemicals. Acetylcholinesterase human, recombinant (expressed in HEK 293 cells, lyophilized powder, ≥1000 U/mg protein; activity for acetylthiocholine chloride was set to 64 U), butyrylcholinesterase from human serum (lyophilized powder, ≥50 U/mg protein; activity for butyrylthiocholine was set to 14 U), boldine (CAS 476-70-0), acetylthiocholine chloride (ATChCl), butyrylthiocholine iodide (BTChI), 5,5’-dithiobis(2-nitrobenzoic) acid (DTNB), and phosphate buffer saline (PBS) pH 7.4 were supplied by Sigma-Aldrich (St. Louis, MO, USA); ethanol was purchased from Penta (Prague, Czech Republic).
2.2. Enzyme Activity Assay. AChE activity was assayed, as triplicate, in standard spectrophotometric cuvette in following way: 400 μl DTNB (1 mmol/l), 25 μl AChE, 450 μl PBS, and 25 μl boldine ethanolic solution, and reaction was started by 100 μl of ATChCl (10 mmol/l). Absorbance was measured immediately and then after 2 min of reaction. BChE activity assay was performed as follows: 400 μl DTNB, 25 μl BChE, 450 μl PBS, and 25 μl boldine ethanolic solution, and reaction was initiated by 100 μl of BTChI (10 mmol/l). Difference in absorbance was measured after 2 minutes.

2.3. Data Processing. Enzyme activity was calculated from absorbance using extinction coefficient for 5-thio-2-nitrobenzoic acid \( \varepsilon = 14,150 \text{ l} \times \text{mol}^{-1} \times \text{cm}^{-1} \) [9]. Dixon plot was constructed in Origin software (Origin, Northampton, MA, USA) and \( K_i \) was then calculated from Michaelis Menten equations.

2.4. Docking Study. UCSF Chimera (version 1.11.2; developed by RBVI with support of NIH, University of California, San Francisco [10]) was used for creating images and molecular modeling. Human AChE (PDB code: 3LII [11]) and BChE (PDB code: 1P0I [12]) were fetched and prepared for docking using Dock Prep tool (added hydrogens, assigned charges). For docking, AutoDock Vina tool was then used, and calculation was run online on Opal server.

3. Results and Discussion

We investigated effect of boldine on both cholinesterases and found out that it is able to inhibit them. Dixon plot revealed noncompetitive mechanism of inhibition which is the most common inhibition mechanism for cholinesterases [13]. The inhibition of AChE by boldine was already investigated and authors reported IC\textsubscript{50} 8.5 μmol/l [8]. We found out \( K_i \) for boldine and human AChE equal to 372.30 μmol/l and \( K_j \) for boldine and human BChE equal to 321.85 μmol/l. \( K_i \) obtained from Dixon plot is directly proportional to IC\textsubscript{50} (Figures 2 and 3). As seen in figures, our findings are not in full agreement with previously achieved result because we found out approximately 40-fold higher IC\textsubscript{50} values for AChE. This difference might be seen in used enzymes, as we used pure form of human AChE, while in the quoted paper AChE is not specified, and authors refer to original paper published by Ellman, who used bovine erythrocyte cholinesterase [14]. Another difference could be in used boldine isomer where hydrogen atom in position 6a gives two optical forms. We used biologically active (S) isomer while the cited paper does not contain specification of the used isomer. Despite the fact that two isomers exist, our docking results suggest that mentioned hydrogen atom is not crucial for molecule interaction with the enzyme. From the aforementioned facts, we claim that boldine is very weak inhibitor with limited impact for pharmacological research. From the achieved results, we can also learn that IC\textsubscript{50} for both cholinesterases is practically the same. This is suggesting that inhibition mechanism of boldine towards cholinesterases lies in inhibition of anionic subsite, as peripheral anionic subsite in BChE is missing [1]; thus inhibition via this site seems to be improbable. Data from experiment with both cholinesterases are summarized in Tables 1 and 2.

Docking of boldine to cholinesterases was not found in the literature; thus we tried to investigate mechanism of this interaction. Grid box for boldine docking into AChE was set around Trp 86 and in BChE structure around Trp 82.
Table 1: Data from AChE inhibition assay.

| Substrate (mM) | Slope (s × I/mol²) | Intercept (s/mol) | Correlation coefficient |
|----------------|--------------------|-------------------|------------------------|
| 0.5            | 3.34 × 10⁶         | 6.31 × 10⁴        | 0.9532                 |
| 0.25           | 3.97 × 10⁶         | 11.64 × 10³       | 0.9985                 |
| 0.125          | 7.13 × 10⁶         | 28.95 × 10³       | 0.9662                 |

Table 2: Data from BChE inhibition assay.

| Substrate (mM) | Slope (s × I/mol²) | Intercept (s/mol) | Correlation coefficient |
|----------------|--------------------|-------------------|------------------------|
| 0.5            | 4.54 × 10⁵         | 9.99 × 10³        | 0.9983                 |
| 0.25           | 5.01 × 10⁶         | 14.67 × 10³       | 0.9924                 |
| 0.125          | 5.79 × 10⁶         | 34.14 × 10³       | 0.9988                 |

Docking showed interaction of boldine with AChE in anionic subsite, where H-bond (2.050 Å) with Asp 74 and OH group (position 9) was predicted and stabilized via π–π interaction of Trp 86 and A ring (Figure 4). Similar situation occurred in BChE, where H-bonds between OH group (position 9) and Glu 197 (1.958 Å) and between OCH₃ group (position 1) and Thr 120 (2.387 Å) were predicted. Stabilization is provided by π–π interaction of Trp 82 and D ring (Figure 5). Our results and also previously published docking study of another aporphine derivate [15] support the aforementioned idea about inhibition via anionic subsite of the enzymes. Another clue lies in mechanism, as noncompetitive inhibitors bind to anionic subsite of the enzyme which can be seen from examples of other cholinesterases inhibitors like tacrine and donepezil [13, 16, 17]. Some aporphine derivatives were reported to exert dual activity towards AChE, when, beside anionic subsite, interacting also with peripheral anionic subsite [18, 19]. Therefore, we checked this possible interaction and found out H-bond (2.127 Å) between OH group (position 2) and Ser 293, stabilized by π–π interaction with Trp 286 and ring A (Figure 6). Facts about boldine interaction with cholinesterases are summarized in Table 3.

Boldine is contained in various plants, widely used in Latin America for decades countries and also exported into Europe (e.g., *Peumus boldus*) [20] and it is known as a low toxic secondary metabolite. This is supported by LD₅₀ values, as 500–1000 mg/kg (p.o., mice and guinea pigs, resp.) is necessary to cause half probability of fatal poisoning [6]. Considering the fact that plasma concentration after administration of 10 mg/kg (p.o., rats) reaches approximately 1 µmol/l of boldine in its peak [21], the aforementioned lethal dose 500 mg/kg would hypothetically reach 50 µmol/l concentration in the blood or blood plasma. However, higher concentration is needed for significant decay of AChE activity. Thus, even lethal dose is not enough to cause cholinesterase inhibition.

4. Conclusion

Effect of boldine on AChE was reinvestigated, and IC₅₀ equal to 372.30 µmol/l was found out compared to previously published 8.5 µmol/l. Thus, we claim that boldine is a cholinesterase inhibitor but it has very low affinity with the enzyme and its inhibitory effect reaches very low scale. We also investigated the effect on BChE (IC₅₀ 321.85 µmol/l) and it was found to be at the same level as that on AChE. We investigated inhibition mechanism of boldine to cholinesterases
Table 3: Found facts about boldine and cholinesterases.

| Enzyme | Inhibition mechanism | IC₅₀ (μmol/l) by spectrophotometry | ΔG (kcal/mol) in silico | Anionic subsite interaction in silico | Peripheral anionic subsite interaction in silico |
|--------|----------------------|-----------------------------------|-------------------------|--------------------------------------|-----------------------------------------------|
| AChE   | Noncompetitive       | 372.30                            | ~7.6 (a. site)           | H-bond: Asp 74                       | H-bond: Ser 293                               |
|        |                      |                                   | ~6.2 (p. site)           | π-π: Trp 86                          | π-π: Trp 82                                   |
| BChE   |                      | 321.85                            | ~9.7                    | H-bond: Thr 120, Glu 197             |                                               |
|        |                      |                                   |                         | π-π: Trp 82                          |                                               |

Figure 5: Presumed position of boldine in BChE cavity. Atom color: white = H, red = O, blue = N, grey (in AChE) and green (in boldine) = C. White lines represent hydrogen bonds.

Figure 6: Presumed position of boldine in peripheral anionic subsite of AChE. Atom color: white = H, red = O, blue = N, grey (in AChE) and green (in boldine) = C. White line represents hydrogen bond.

and proposed inhibition mechanism of boldine to AChE by docking. Results are supported by previously published findings and our experimental data and indicate inhibition via anionic subsite. We also discussed theoretical effect of boldine on AChE in real conditions. Considering the conclusions, boldine appears weak inhibitor of cholinesterases, not well suited for pharmacological research. On the other hand, its ability to inhibit cholinesterases is attributed to its biological effect though the only low manifestation is expected.

Conflicts of Interest
The authors declare no conflicts of interest.

Acknowledgments
This work was supported by the Ministry of Defence of the Czech Republic—long-term organization development plan Medical Aspects of Weapons of Mass Destruction of the Faculty of Military Health Sciences, University of Defence.
References

[1] M. Pohanka, “Cholinesterases, a target of pharmacology and toxicology,” *Biomedical Papers*, vol. 155, no. 3, pp. 219–230, 2011.

[2] M. Pohanka, “Butyrylcholinesterase as a biochemical marker,” *Bratislava Medical Journal*, vol. 114, no. 12, pp. 726–734, 2013.

[3] M. Pohanka, “Acetylcholinesterase inhibitors: a patent review (2008 present),” *Expert Opinion on Therapeutic Patents*, vol. 22, no. 8, pp. 871–886, 2012.

[4] P. L. Julian and J. Pikl, “Studies in the indole series. III. On the synthesis of phystostigmine,” *Journal of the American Chemical Society*, vol. 57, no. 3, pp. 539–544, 1935.

[5] S. Lilienfeld, “Galantamine—a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease,” *CNS Drug Reviews*, vol. 8, no. 2, pp. 159–176, 2002.

[6] P. O’Brien, C. Carrasco-Pozo, and H. Speisky, “Boldine and its antioxidant or health-promoting properties,” *Chemico-Biological Interactions*, vol. 159, no. 1, pp. 1–17, 2006.

[7] H. Speisky and B. K. Cassels, “Boldo and boldine: an emerging case of natural drug development,” *Pharmacological Research*, vol. 29, no. 1, pp. 1–12, 1994.

[8] A. Mollataghi, E. Coudiere, A. H. A. Hadi et al., “Anti-acetylcholinesterase, anti-α-glucosidase, anti-leishmanial and anti-fungal activities of chemical constituents of Beilschmiedia species,” *Fitoterapia*, vol. 83, no. 2, pp. 298–302, 2012.

[9] P. Eyer, F. Worek, D. Kiderlen et al., “Molar absorption coefficients for the reduced ellman reagent: reassessment,” *Analytical Biochemistry*, vol. 312, no. 2, pp. 224–227, 2003.

[10] E. F. Pettersen, T. D. Goddard, C. C. Huang et al., “UCSF Chimera—a visualization system for exploratory research and analysis,” *Journal of Computational Chemistry*, vol. 25, no. 13, pp. 1605–1612, 2004.

[11] H. Dvir, I. Silman, M. Harel, T. L. Rosenberry, and J. L. Sussman, “Acetylcholinesterase: from 3D structure to function,” *Chemico-Biological Interactions*, vol. 187, pp. 10–22, 2010.

[12] Y. Nicolet, O. Lockridge, P. Masson, J. C. Fontecilla-Camps, and F. Nachon, “Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products,” *The Journal of Biological Chemistry*, vol. 278, no. 42, pp. 41141–41147, 2003.

[13] M. Pohanka, “Biosensors containing acetylcholinesterase and butyrylcholinesterase as recognition tools for detection of various compounds,” *Chemical Papers*, vol. 69, no. 1, pp. 4–16, 2015.

[14] G. L. Ellman, K. D. Courtney, V. Andres Jr., and R. M. Featherstone, “A new and rapid colorimetric determination of acetylcholinesterase activity,” *Biochemical Pharmacology*, vol. 7, no. 2, pp. 88–95, 1961.

[15] Z. Yang, Z. Song, W. Xue et al., “Synthesis and structure-Activity relationship of nuciferine derivatives as potential acetylcholinesterase inhibitors,” *Medicinal Chemistry Research*, vol. 23, no. 6, pp. 3178–3186, 2014.

[16] J. K. Marquis, “Pharmacological significance of acetylcholinesterase inhibition by tetrahydroaminoacridine,” *Biochemical Pharmacology*, vol. 40, no. 5, pp. 1071–1076, 1990.

[17] D. G. Wilkinson, “The pharmacology of donepezil: a new treatment for Alzheimer’s disease,” *Expert Opinion on Pharmacotherapy*, vol. 1, no. 1, pp. 121–135, 1999.

[18] H. Tang, Y.-B. Wei, C. Zhang et al., “Synthesis, biological evaluation and molecular modeling of oxoisoporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase,” *European Journal of Medicinal Chemistry*, vol. 44, no. 6, pp. 2523–2532, 2009.

[19] S. Pecic, M. A. McAnuff, and W. W. Harding, “Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations,” *Journal of Enzyme Inhibition and Medicinal Chemistry*, vol. 26, no. 1, pp. 46–55, 2011.

[20] N. Backhouse, C. Delporte, M. Givernau, B. K. Cassels, A. Valenzuela, and H. Speisky, “Anti-inflammatory and antipyretic effects of boldine,” *Agents and Actions Supplements*, vol. 42, no. 3–4, pp. I14–I17, 1994.

[21] I. Cermanova, A. Prasnicka, E. Dolezelova et al., “Pharmacokinetics of boldine in control and mrp2-deficient rats,” *Physiological Research*, vol. 65, pp. S489–S497, 2016.